New research suggests that people who discontinue blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who end conventional lifestyle regimens.
Published data in a prominent medical journal demonstrates that while overweight individuals can lose substantial amounts of their body weight while using the jabs, the mass returns at an average rate of 0.8 kg per month upon discontinuation.
"People purchasing such medications should be cognizant of the risk of quick weight regain when the medication concludes," warns expert Dr. Susan Jebb.
That rate of recovery means a reversion to original weight in about a year and a half.
Weighing Therapies
The study, which examined dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with other pills.
Researchers point out that individuals who lose weight through dieting usually see a slower creep back—approximately 0.1 kg a month—after stopping.
Explaining the Quick Regain
Doctors believe the mechanism of the drugs accounts for the amplified regain.
The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate appetite.
"Artificially providing the hormone levels far above than normal could lead to the system to generate a reduced amount of its endogenous hormone, and may also reduce responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement means appetite is unsuppressed, making binge eating much more probable."
A Lifelong Disease?
Medical guidelines advise the injections for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals argue that, given the likelihood of weight regain, the therapy should be considered ongoing.
This view is echoed by pharmaceutical companies, who note that the results "highlight the long-term character of excess weight," similar to managing conditions like diabetes.
User Accounts
People who have discontinued the jabs report a sudden return of appetite.
"I experienced a trigger flipping and I was suddenly starving," said an individual.
This difficulty is exacerbated if users have not developed sustainable lifestyle or habit changes during therapy.
Significant Adoption
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is greater among women than males.
- The middle-aged demographic shows the highest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Ultimately, researchers caution that while the jabs are effective agents for weight loss, they are not a magic cure and long-term success likely depends on integrated behavioural changes.
